This clinical trial is focused on studying heart failure, a condition where the heart doesn’t pump blood as well as it should. The study aims to compare two treatments: spironolactone and eplerenone. Both of these medications are known as aldosterone antagonists, which help the body get rid of excess salt and water, reducing the workload on the heart.
The purpose of the study is to see how effective these two medications are in reducing the risk of death in patients with heart failure who have a reduced ejection fraction. Ejection fraction is a measurement of how much blood the left ventricle of the heart pumps out with each contraction. Patients participating in the study will be monitored over a period of time to observe the effects of the medications on their heart health.
During the study, participants will receive either spironolactone, eplerenone, or a placebo. The study will track the occurrence of death or hospitalization due to heart failure as key outcomes. This research will help determine if spironolactone and eplerenone are comparable in their effectiveness for treating heart failure. The study is expected to continue until the end of 2028.



Denmark